trending Market Intelligence /marketintelligence/en/news-insights/trending/61RFq1iDwQyjuf4kJ0ttCw2 content esgSubNav
In This List

Report: Bayer urges US appeals court to quash $25M Roundup decision

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Report: Bayer urges US appeals court to quash $25M Roundup decision

Bayer AG urged a U.S. federal appeals court to quash a verdict that ordered the company to pay $25 million to a man who alleged that his cancer was caused by the company's weedkiller Roundup, Reuters reported.

In March, a jury in San Francisco federal court ordered Bayer to pay $80 million to Edwin Hardeman who claimed that he developed non-Hodgkin lymphoma after using Roundup, which the German pharma and chemicals giant inherited following the $62.5 billion acquisition of Monsanto Co. in 2018.

The trial court judge slashed the $80 million verdict to $25 million in July.

Bayer said in a filing in the U.S. Court of Appeals for the 9th Circuit that the decision was contrary to regulatory findings. The company's arguments are centered on findings by the U.S. Environmental Protection Agency that glyphosate — the main ingredient in Roundup — is not a cancer-causing substance and not a risk to public health when used as per its label instructions, said the report.

The company is facing lawsuits from about 42,700 plaintiffs in the U.S. who allege that Roundup is responsible for causing cancer.